Blue Therapeutics advances BLUE-181, a novel non-narcotic painkiller, as lead clinical candidate

June 18th, 2018 (Cambridge, MA) – Blue Therapeutics, a biotechnology company developing safer, more effective painkillers using its novel GPCR heterodimer targeting platform, announced today the advancement of its lead compound BLUE-181 into IND-enabling studies towards FDA approval for human clinical trials.

In preclinical studies conducted by the company, BLUE-181 demonstrated up to 50x the pain relieving potency of morphine while lacking the common and dangerous side effects of opioids, including withdrawal, tolerance, respiratory depression, and reward seeking behavior.

“The proof-of-concept is there,” said Blue’s CSO Dr. Ajay Yekkirela. “BLUE-181 works in models of acute pain and neuropathic pain, through oral and intravenous routes of administration, and doesn’t possess addictive side effects. The technology performs just as we hoped it would.”

“Our results to date have confirmed our novel approach and justified moving forward,” said Dr. Michio Painter, CEO of Blue Therapeutics. “We are thankful to the National Institute on Drug Abuse and the Department of Defense for supporting this key work.”

FDA required safety studies on BLUE-181 are underway, and preclinical research continues on additional compounds and applications for the company’s GPCR heterodimer platform.

About Blue Therapeutics (www.bluetherapeutics.com)

Blue Therapeutics is an early-stage drug development company focused on developing safe, effective painkillers for acute and chronic pain. The company is supported by the National Institute on Drug Abuse, The Department of Defense, and the Roddenberry Foundation.

Contact:

Michio Painter, PhD
michio@bluetherapeutics.com